+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Phase I study of stereotactic body radiation therapy for centrally located stage IA non-small cell lung cancer (JROSG10-1)



Phase I study of stereotactic body radiation therapy for centrally located stage IA non-small cell lung cancer (JROSG10-1)



International Journal of Clinical Oncology 22(5): 849-856



To investigate the maximum tolerated dose (MTD) and recommended dose (RD) of stereotactic body radiation therapy (SBRT) for centrally located stage IA non-small cell lung cancer (NSCLC). Five dose levels, ranging from of 52 to 68 Gy in eight fractions, were determined; the treatment protocol began at 60 Gy (level 3). Each dose level included 10 patients. Levels 1-2 were indicated if more than four patients exhibited dose-limiting toxicity (DLT), which was defined as an occurrence of a grade 3 (or worse) adverse effect within 12 months after SBRT initiation. MTD was defined as the lowest dose level at which more than four patients exhibited DLT. Ten patients were enrolled in the level 3 study. One patient was considered unsuitable because of severe emphysema. Therefore, nine patients were evaluated and no patient exhibited DLT. The level 3 results indicated that we should proceed to level 4 (64 Gy). However, due to the difficulty involved in meeting the dose constraints, further dose escalation was not feasible and the MTD was found to be 60 Gy. The RD of SBRT for centrally located stage IA NSCLC was 60 Gy in eight fractions.

(PDF emailed within 0-6 h: $19.90)

Accession: 060088554

Download citation: RISBibTeXText

PMID: 28466183

DOI: 10.1007/s10147-017-1125-y


Related references

Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer. International Journal of Radiation Oncology, Biology, Physics 72(4): 967-971, 2008

Feasibility of helical tomotherapy in stereotactic body radiation therapy for centrally located early stage non‒small-cell lung cancer or lung metastases. International Journal of Radiation Oncology, Biology, Physics 81(3): 856-862, 2011

Proton stereotactic body radiation therapy for clinically challenging cases of centrally and superiorly located stage I non-small-cell lung cancer. International Journal of Radiation Oncology, Biology, Physics 80(4): 1015-1022, 2011

Proton stereotactic body radiation therapy for clinically challenging cases of centrally and superiorly located stage I non-small-cell lung cancer: in regards to Register et al. Int J Radiat Oncol Biol Phys 2011;80:1015-1022. International Journal of Radiation Oncology, Biology, Physics 82(1): 492; Author Reply 492, 2012

Primary Study Endpoint Analysis for NRG Oncology/RTOG 0813 Trial of Stereotactic Body Radiation Therapy (SBRT) for Centrally Located Non-Small Cell Lung Cancer (NSCLC). International Journal of Radiation Oncology*biology*physics 94(1): 5-6, 2016

Phase 2 Study of Stereotactic Body Radiation Therapy and Stereotactic Body Proton Therapy for High-Risk, Medically Inoperable, Early-Stage Non-Small Cell Lung Cancer. International Journal of Radiation Oncology, Biology, Physics 101(3): 558-563, 2018

Stereotactic ablative radiation therapy for centrally located early stage or isolated parenchymal recurrences of non-small cell lung cancer: how to fly in a "no fly zone". International Journal of Radiation Oncology, Biology, Physics 88(5): 1120-1128, 2014

Stereotactic Body Radiation Therapy (SBRT) For Centrally Located Primary and Recurrent Non-Small Cell Lung Cancer: Analysis of Toxicity and Local Control. International Journal of Radiation Oncology*biology*physics 93(3): E418-E419, 2015

Stereotactic body radiotherapy for centrally located stage I non-small cell lung cancer. Translational Lung Cancer Research 8(1): 58-69, 2019

The potential role of respiratory motion management and image guidance in the reduction of severe toxicities following stereotactic ablative radiation therapy for patients with centrally located early stage non-small cell lung cancer or lung metastases. Frontiers in Oncology 4: 151, 2014

Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch(®) patient registry. Radiation Oncology 10: 113, 2016

Stereotactic ablative radiation therapy for centrally located recurrences of non-small cell lung cancer: in regard to Chang et al. International Journal of Radiation Oncology, Biology, Physics 89(5): 1141-1142, 2014

A Prospective Phase 2 Study Evaluating Safety and Efficacy of Combining Stereotactic Body Radiation Therapy With Heat-based Ablation for Centrally Located Lung Tumors. International Journal of Radiation Oncology, Biology, Physics 101(3): 564-573, 2018

Stereotactic body radiation therapy of early-stage non-small-cell lung carcinoma: phase I study. International Journal of Radiation Oncology, Biology, Physics 63(4): 1010-1015, 2005

Stereotactic Body Radiotherapy for Centrally Located Non-small Cell Lung Cancer. Zhongguo Fei Ai Za Zhi 21(5): 413-418, 2018